Relypsa

Relypsa, Inc. is a publicly traded (Nasdaq:RLYP), biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. We submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company’s lead product candidate, Patiromer for Oral Suspension, which is being developed for the treatment of hyperkalemia Hyperkalemia is a serious condition defined as abnormally elevated levels of potassium in the blood. Relypsa has global royalty-free commercialization rights to Patiromer FOS, and intellectual property protection in the U.S. until at least 2030. We use our proprietary polymer drug discovery and development technology to advance our pipeline and pursue commercially synergistic opportunities.